Sign in
CompletedPhase 1

Alirocumab in Patients with Sepsis

Key facts

Who runs it
Jonathan Sevransky
Where
Atlanta, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
50 people enrolled
Started
4 Jan 2023
Ended
23 Feb 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Alirocumab
  • Placebo
Record updated
24 March 2025

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Suspected or confirmed infection as evidenced by ordering of blood cultures and administration of at least one antimicrobial agent
  • Acute respiratory or cardiovascular organ dysfunction attributed to sepsis as evidenced by at least one of the following requirements:; Vasopressor Requirement - Continuous infusion of norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine or other vasopressor agents at any dose for greater than 1 hour and required to maintain a mean arterial pressure ≥ 65 mm Hg despite intravenous crystalloid infusion of at least 1000cc; Respiratory Support Requirement - Acute hypoxemic respiratory failure defined as persistent hypoxemia requiring (1) intubation and mechanical ventilation, or (2) positive pressure ventilation via tight-fitting face mask or (3) high flow nasal cannula ≥ 45 liters per minute (LPM) flow and fraction of inspired oxygen (FiO2) ≥ 0.40
  • Anticipated or confirmed intensive care unit (ICU) admission

Who cannot take part

  • Requirement of more than 6 liters (L) nasal cannula (NC) if not receiving invasive mechanical ventilation
  • Chronic cardiovascular failure requiring home mechanical hemodynamic support or home chemical hemodynamic support
  • Known allergy or known contraindication to alirocumab
  • Chronic disease/illness that, in the opinion of the site investigator, have an expected lifespan of < 30 days unrelated to current sepsis diagnosis (e.g, stage IV malignancy, neurodegenerative disease, etc.)
  • Organ dysfunction present > 24 hours at time randomization
  • Limitations of care (defined as refusal of cardiovascular and respiratory support described under inclusion criteria) including "do not intubate" (DNI) status
  • Development of sepsis while in the hospital ( i.e not present on admission to hospital)
  • Chronic hypoxemia requiring supplemental non-invasive oxygen or home mechanical ventilation
  • Pregnancy
  • Prisoner or incarceration
  • Current participation in another interventional pharmaceutical research study for sepsis
  • Inability or unwillingness of subject or legal surrogate/representative to give written informed consent

Where in United States

  • Emory University HospitalAtlanta, United States
  • Grady Memorial HospitalAtlanta, United States

About the trial

What the trial wants to find out

The purpose of this study is to determine whether the drug alirocumab, which may lower cholesterol, can reduce the amount of inflammation caused by an infection that has caused either low blood pressure or difficulty breathing. Participants will be randomized to receive a single IV infusion of alirocumab or a placebo.

The 2 groups in the trial

  • AlirocumabTreatment being tested

    Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive alirocumab.

  • PlaceboPlacebo, for comparison

    Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive a placebo to match alirocumab.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PCSK9 and Lipid Metabolism in Sepsis (PALMS) : a Two-center, Phase 1b Randomized, Placebo-controlled, Double-blind, Clinical Trial of Alirocumab in Patients with Sepsis
Record updated
24 March 2025